These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22812556)

  • 61. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers.
    Rosandich PA; Kelley JT; Conn DL
    Curr Opin Rheumatol; 2004 May; 16(3):192-8. PubMed ID: 15103244
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunogenicity - implications for rheumatoid arthritis treatment.
    Solomon G
    Bull Hosp Jt Dis (2013); 2013; 71(3):200-3. PubMed ID: 24151945
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Switching anti-TNF-alpha agents: what is the evidence?
    Erickson AR; Mikuls TR
    Curr Rheumatol Rep; 2007 Oct; 9(5):416-20. PubMed ID: 17915098
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
    Jani M; Dixon WG; Chinoy H
    Rheumatology (Oxford); 2018 Nov; 57(11):1896-1907. PubMed ID: 29325166
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review.
    Lopez-Olivo MA; Kallen MA; Ortiz Z; Skidmore B; Suarez-Almazor ME
    Arthritis Rheum; 2008 Nov; 59(11):1625-38. PubMed ID: 18975351
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice.
    Blake T; Rao V; Hashmi T; Erb N; O'Reilly SC; Shaffu S; Obrenovic K; Packham J
    BMC Musculoskelet Disord; 2014 Sep; 15():290. PubMed ID: 25182696
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.
    DeWitt EM; Lin L; Glick HA; Anstrom KJ; Schulman KA; Reed SD
    Clin Ther; 2009 Aug; 31(8):1871-80; discussion 1858. PubMed ID: 19808146
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Advances in targeted therapy: safety of biological agents.
    Keystone EC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii34-6. PubMed ID: 14532146
    [No Abstract]   [Full Text] [Related]  

  • 69. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 70. [Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].
    Rubbert-Roth A
    Z Rheumatol; 2015 Jun; 74(5):406-13. PubMed ID: 26031285
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune modulation of rheumatoid arthritis.
    Pappas DA; Geraldino-Pardilla L; Bathon JM
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):873-89. PubMed ID: 22265267
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.
    Franklin JP; Symmons DP; Silman AJ
    Ann Rheum Dis; 2005 May; 64(5):657-8. PubMed ID: 15834052
    [No Abstract]   [Full Text] [Related]  

  • 73. Pharmacotherapy: How well can we compare different biologic agents for RA?
    Smolen JS
    Nat Rev Rheumatol; 2010 May; 6(5):247-8. PubMed ID: 20431550
    [No Abstract]   [Full Text] [Related]  

  • 74. Biologic agents in rheumatology: safety considerations.
    Lee SJ; Kavanaugh A
    Rheum Dis Clin North Am; 2006 Dec; 32 Suppl 1():3-10. PubMed ID: 17410696
    [No Abstract]   [Full Text] [Related]  

  • 75. Rheumatoid arthritis: strategy more important than agent.
    Sokka T; Pincus T
    Lancet; 2009 Aug; 374(9688):430-2. PubMed ID: 19665630
    [No Abstract]   [Full Text] [Related]  

  • 76. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
    Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
    Ann Rheum Dis; 2009 Apr; 68(4):456-9. PubMed ID: 19286904
    [No Abstract]   [Full Text] [Related]  

  • 77. Renal manifestations of rheumatological disorders.
    Biswas S; Paul R
    J Indian Med Assoc; 2013 Aug; 111(8):542-4, 552. PubMed ID: 24783393
    [No Abstract]   [Full Text] [Related]  

  • 78. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines.
    Singh R; Robinson DB; El-Gabalawy HS
    Curr Opin Rheumatol; 2005 May; 17(3):274-9. PubMed ID: 15838236
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of rheumatoid arthritis 2012: a Canadian state of the art.
    Karsh J
    J Rheumatol; 2012 Aug; 39(8):1497-9. PubMed ID: 22859527
    [No Abstract]   [Full Text] [Related]  

  • 80. NICE recommends widening choice of biological drugs for patients with rheumatoid arthritis.
    Mayor S
    BMJ; 2010 Jun; 340():c3477. PubMed ID: 20587556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.